ArticleEndocrinology, diabetes & metabolism2026
Circular RNAs in Diabetic Foot Ulcers: A Scoping Review of Clinical, Preclinical, and In Silico Evidence on Diagnostic and Therapeutic Potentials.
Article in Endocrinology, diabetes & metabolism, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Hsa_circ_0006969 aggravates keratinocytes from high-glucose injury by sponging miR-375 to promote USP10 and SCD expression.Functional & integrative genomics · 2026Article
- Circular RNAs in Diabetic Foot Ulcers: A Scoping Review of Clinical, Preclinical, and In Silico Evidence on Diagnostic and Therapeutic Potentials.Endocrinology, diabetes & metabolism · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveDiabetic foot ulcers (DFUs) involve chronic inflammation, impaired angiogenesis, oxidative stress, and disrupted fibroblast-keratinocyte interactions. Circular RNAs (circRNAs), a category of stable non-coding RNAs, have become essential regulators of these processes; nevertheless, their comprehensive functions in DFUs are still inadequately characterised. This scoping review integrated clinical, preclinical, and in silico evidence on circRNAs in DFUs to assess their diagnostic, mechanistic, and therapeutic potential.
methodsSystematic searches of MEDLINE, EMBASE, Web of Science, and Google Scholar were conducted on July 16, 2025, according to the PRISMA-ScR guidelines. Eligible papers included clinical investigations of circRNAs in the tissues of patients with DFUs, preclinical animal models assessing circRNA-based therapies, and computational predictions of circRNA-miRNA-mRNA networks. Information was collected on circRNA expression, molecular targets, clinical associations, and therapeutic effects.
resultsTwenty-two studies (7 clinical, 13 preclinical, 2 in silico) were selected. Clinical studies found hsa_circ_PRKDC, hsa_circ_072697, hsa_circ_080968, and hsa_circ_0000907 to be associated with wound severity, tissue perfusion, and keratinocyte proliferation in patients with diabetic foot ulcers. Preclinical studies showed that delivery of mmu_circHIPK3, mmu_circMYO9B, and mmu_circ_Astn1 via exosomes or nanoparticles improved angiogenesis, epithelial regeneration, and wound closure. However, the silence of mmu_circ_0005654 reduced ferroptosis and inflammation. In silico analyses identified potential regulatory axes, such as hsa_circ_0089761/miR-146a-5p/SMAD4 (Mothers against decapentaplegic homologue 4) and hsa_circ_0049271/miR-24-3p/JUNB, that were associated with inflammatory-angiogenic pathways in this disease.
conclusionsCircRNAs hold promise for the diagnosis and treatment of DFUs by modulating angiogenesis, inflammation, oxidative stress, and epithelial repair. Standard network-guided therapies are essential to translate circRNA-based strategies into clinical practice.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.